DUBLIN, Ireland – Trino Therapeutics Ltd., a spinout from Trinity College Dublin (TCD), raised €9 million (US$11.6 million) in a Series A round to move PH46A, an oral, first-in-class indane dimer, into clinical trials in ulcerative colitis.
BTG plc grossed £106.3 million (US$160.2 million) in an accelerated book build last week in order to fund the acquisition of two businesses: the targeted therapies division of Nordion Inc. and Ekos Corp.
DUBLIN, Ireland – Trino Therapeutics Ltd., a spinout from Trinity College Dublin (TCD), raised €9 million (US$11.6 million) in a Series A round to move PH46A, an oral, first-in-class indane dimer, into clinical trials in ulcerative colitis.
BTG plc grossed £106.3 million (US$160.2 million) in an accelerated book build in order to fund the acquisition of two businesses: the targeted therapies division of Nordion Inc. and Ekos Corp.
The growth equity arm of Novo A/S has clocked up its first major pharmaceutical investment, a $700 million buyout of generic antibiotics developer and manufacturer Xellia Pharmaceuticals AS, under a new investment strategy it formulated more than a year ago.
The growth equity arm of Novo A/S has clocked up its first major pharmaceutical investment, a $700 million buyout of generic antibiotics developer and manufacturer Xellia Pharmaceuticals AS, under a new investment strategy it formulated more than a year ago.
DUBLIN, Ireland – Elan Corp. plc continues to execute its M&A strategy at a dizzying pace, while its would-be acquirer, Royalty Pharma, has tabled a revised offer for the company, worth $12.50 per share or $6.37 billion.
DUBLIN, Ireland – Elan Corp. plc continues to execute its M&A strategy at a dizzying pace, while its would-be acquirer, Royalty Pharma has tabled a revised offer for the company, worth $12.50 per share or $6.37 billion.
Cosmo Pharmaceuticals SpA landed a hefty chunk of upside, that all-too-elusive commodity, by grossing $89.2 million from a sale of Santarus Inc. stock. The transaction will enable the already-profitable company to begin paying dividends to its shareholders.
